Ligand Pharmaceuticals Incorporated (LGND) fair value analysis

Nasdaq · Updated 2026-09-07

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs for various therapeutic areas including oncology, cardiovascular disease, and metabolic disorders. The company operates primarily in the United States with research, development, and commercial operations across multiple locations.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, LGND is trading at more than a 25% premium to estimated fair value.

LGND currently ranks #108 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $292.04
Sector: Healthcare
12-month range: $179.07–$312.01

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: B
Leverage: Moderate
RSI zone: Neutral
50/200-day trend: Uptrend
52-week position: The top quarter of its range

What our data shows for LGND

Our model validated 17 trailing price-to-earnings windows for LGND, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $179.07–$312.01.
The 14-day relative strength index sits at a neutral 41.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for LGND
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent LGND news

TickrTrends' derived news-sentiment signal for LGND is currently mixed, computed from recent coverage.

Ligand to Participate in September Investor Conferences (manilatimes.net, 2026-08-26)
TickrTrends take: Ligand Pharmaceuticals' participation in September investor conferences provides an opportunity for management to address investor concerns and discuss the company's pipeline and financial prospects directly with the market. Given TickrTrends' current assessment that LGND is overvalued, investors attending these conferences may scrutinize management's guidance on revenue growth, margin expansion, and return on capital to determine whether the current valuation is justified. For valuation-focused readers, these conferences represent a key moment to evaluate whether management commentary supports the stock's recent pricing or suggests further compression may be warranted.
Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript (seekingalpha.com, 2026-08-06)
TickrTrends take: Ligand Pharmaceuticals operates in the Healthcare sector where valuation multiples can vary significantly based on pipeline strength and revenue predictability. With TickrTrends currently assessing LGND as overvalued, investors monitoring the Q2 2026 earnings call should focus on whether management commentary supports the current market price through concrete revenue growth metrics, margin expansion, or material pipeline developments. The gap between market valuation and fundamental performance will be particularly relevant for readers evaluating whether the overvalued designation reflects genuine concerns about pricing relative to near-term earnings power or cash generation.
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026 (manilatimes.net, 2026-07-23)
TickrTrends take: Ligand Pharmaceuticals is scheduled to release its second quarter 2026 financial results on August 6, 2026, providing investors with updated operational and financial metrics for assessment. Given that TickrTrends currently rates LGND as overvalued within the Healthcare sector, the August earnings report will be a key opportunity to evaluate whether the company's actual financial performance supports its current market valuation. Valuation-focused observers should monitor revenue trends, profitability margins, and guidance updates to determine if recent market pricing has properly reflected the company's underlying fundamentals.

What people are saying

Follow the LGND conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is LGND stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), LGND is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is LGND's TickrTrends verdict?

LGND's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does LGND compare to other Healthcare stocks?

LGND ranks #108 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is LGND overbought or oversold?

LGND's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

LGND vs ACAD · LGND vs ALKS · LGND vs AMGN · LGND vs CDNA · LGND vs DGX